| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
MNPR
Monopar Therapeutics Inc
|
Jul 01, 2026 | BUY |
Strong Buy
-2.8% avg upside
18 analysts
|
$117.00
17.20% Upside
|
· |
|
FTH
Faeth Therapeutics
|
Jul 01, 2026 | BUY |
Strong Buy
+23.7% avg upside
13 analysts
|
$55.00
66.16% Upside
|
· |
|
NRIX
Nurix Therapeutics
|
Jul 01, 2026 | BUY |
Strong Buy
+37.1% avg upside
28 analysts
|
$32.00
39.22% Upside
|
+3.9% |
|
KYMR
Kymera Therapeutics
|
Jun 25, 2026 | BUY |
Strong Buy
-9.4% avg upside
36 analysts
|
$134.00
19.59% Upside
|
+2.5% |
|
VSTM
Verastem
|
Jun 24, 2026 | BUY |
Strong Buy
+171.4% avg upside
24 analysts
|
$18.00
223.16% Upside
|
+31.9% |
|
AVBP
ArriVent BioPharma, Inc.
|
May 29, 2026 | BUY |
Strong Buy
+29.8% avg upside
15 analysts
|
$42.00
29.01% Upside
|
+8.9% |
|
AARD
Aardvark Therapeutics, Inc.
|
May 15, 2026 | HOLD |
Buy
+208.1% avg upside
12 analysts
|
— | +14.1% |
|
IPHA
Innate Pharma
|
May 13, 2026 | BUY |
Strong Buy
+264.8% avg upside
10 analysts
|
$8.00
346.87% Upside
|
+53.0% |
|
AAPG
Ascentage Pharma Group International Unsponsored ADR
|
May 13, 2026 | BUY |
Strong Buy
+128.8% avg upside
10 analysts
|
$48.00
149.56% Upside
|
-19.4% |
|
ARVN
Arvinas Holding Company
|
May 13, 2026 | BUY |
Strong Buy
+239.4% avg upside
27 analysts
|
$18.00
117.60% Upside
|
-16.2% |
|
CATX
Perspective Therapeutics
|
May 12, 2026 | BUY |
Strong Buy
+267.5% avg upside
22 analysts
|
$14.00
359.02% Upside
|
-20.2% |
|
BCAX
Bicara Therapeutics Inc.
|
May 11, 2026 | BUY |
Strong Buy
+10.8% avg upside
14 analysts
|
$28.00
0.30% Downside
|
+26.1% |
|
IBRX
ImmunityBio
|
May 08, 2026 | BUY |
Strong Buy
+42.8% avg upside
12 analysts
|
$12.00
52.36% Upside
|
-7.4% |
|
VKTX
Viking Therapeutics
|
May 01, 2026 | BUY |
Strong Buy
+89.3% avg upside
31 analysts
|
$125.00
229.22% Upside
|
+29.5% |
|
PVLA
Palvella Therapeutics
|
Apr 01, 2026 | BUY |
Strong Buy
+11.9% avg upside
27 analysts
|
$215.00
43.71% Upside
|
+20.2% |
|
FHTX
Foghorn Therapeutics
|
Mar 11, 2026 | BUY |
Strong Buy
+120.1% avg upside
17 analysts
|
$11.00
104.45% Upside
|
-24.2% |
|
LYRA
Lyra Therapeutics
|
Jun 03, 2025 | HOLD |
Hold
+6044.8% avg upside
7 analysts
|
— | -97.6% |
|
KURA
Kura Oncology
|
May 23, 2025 | HOLD |
Strong Buy
+132.2% avg upside
26 analysts
|
— | +99.5% |
|
LEGN
Legend Biotech
|
May 23, 2025 | BUY |
Strong Buy
+153.9% avg upside
27 analysts
|
$91.00
254.54% Upside
|
+1.6% |
|
TCRX
TScan Therapeutics
|
May 21, 2025 | BUY |
Strong Buy
+807.2% avg upside
12 analysts
|
$12.00
1190.36% Upside
|
-22.7% |
|
ELVN
Enliven Therapeutics
|
May 13, 2025 | BUY |
Strong Buy
+1.8% avg upside
14 analysts
|
$42.00
18.82% Downside
|
+117.5% |
|
JANX
Janux Therapeutics Inc
|
May 09, 2025 | BUY |
Strong Buy
+183.4% avg upside
21 analysts
|
$100.00
533.75% Upside
|
-44.5% |
|
BCAB
BioAtla
|
May 07, 2025 | BUY |
Strong Buy
+2316.7% avg upside
13 analysts
|
$10.00
146.36% Upside
|
-80.6% |
|
IDYA
IDEAYA Biosciences
|
Apr 14, 2025 | BUY |
Strong Buy
+33.5% avg upside
29 analysts
|
$62.00
69.14% Upside
|
+89.1% |
|
CARM
Carisma Therapeutics
|
Apr 01, 2025 | HOLD |
Buy
+56150.0% avg upside
11 analysts
|
— | -85.5% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.